Portraits of Janusz Kulagowski - Drug Di

Janusz Kulagowski Ph.D

Drug Discovery Manager, Parkinson's UK

Prior to taking on his current role as Drug Discovery Manager at Parkinson's UK, Jan spent 20 years working in neuroscience at Merck & Co. Jan also bring expertise of contract research from his position at Argenta Discovery.

Alan Naylor

Alan Naylor Ph.D
Drug Discovery Advisory Panel member

Following a long career culminating as VP and Director of Medicinal Chemistry at GSK, Alan is now an independent drug discovery consultant. He is a co-inventor of Serevent (salmeterol), a marketed drug for use in asthma and COPD, and has been a member of several Wellcome Trust and CRUK committees.

Ann Hayes Ph.D
Drug Discovery Advisory Panel member

Following her Ph.D, Ann spent 22 years at Glaxo and was appointed Therapeutic Director for CNS diseases in 1995. In 2001, Ann set up as an independent consultant and has since co-founded 3 companies and sat on the board of several others.  She now consults for a number of companies and venture capitalists, alongside advising charitable organisations including Alzhemer's Research UK and the Wellcome Trust.

Michael Rowley

Michael Rowley Ph.D
Drug Discovery Advisory Panel member

Mike has held several senior positions at both Merck Sharp and Dohme (MSD) in the UK, Italy and Switzerland, and AstraZeneca in Sweden. He led teams which identified the marketed drugs Isentress (raltegravir) for HIV infection, Zapatier for HCV infection and niraparib for breast and ovarian cancer, which has been filed with regulatory authorities.


Professor David Dexter

Deputy Research Director, Parkinson's UK

Professor in Neuropharmacology, with expertise in the pathophysiology of neurodegenerative conditions and drug development. David was previously Deputy Head, Division of Brain Sciences at Imperial College London. In 2002 he established the Parkinson’s UK Tissue Bank and served as the Scientific Director. 

Richard Morphy 

Drug Discovery Manager, Parkinson's UK

Richard has over 25 years of experience as a medicinal chemist, having worked for a diverse range of organizations from biotech to large pharma. At Celltech, he researched new treatments for cancer and inflammation. He then joined Organon in Scotland as chemistry section head, developing expertise across a range of CNS diseases, and establishing a number of drug discovery partnerships. He has also worked with several US pharma companies, Schering Plough, MSD and, most recently, Eli Lilly where his research was predominantly in the neuroscience and autoimmune disease areas. 

John Davis Ph.D
Drug Discovery Advisory Panel member

John has 20+ years of drug discovery expertise from target to phase IIa and has helped steer a dozen drug candidates into clinical development and to four positive proof of concepts. After his Ph.D and post-doctoral training, John joined GlaxoSmihKline. He left to form the spinout company Convergence Pharmaceuticals and later served as Director of Discovery for Selcia Ltd. and cofounded Cypralis Ltd. Since 2015 John has led the Alzheimer’s Research UK Drug Discovery Institute based at the University of Oxford.